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Introduction {#sec006}
============

Diabetes mellitus (DM) is a chronic condition that occurs when the body cannot produce or effectively utilize insulin, which results in increased levels of glucose in the blood stream (hyperglycaemia) causing metabolic disorders of many organs over time \[[@pone.0206372.ref001]\]. During the past few decades, socio-economic development, urbanization and life style changes have led to most countries undergoing a significant epidemiological transition, and this has resulted in a rapidly increasing burden of DM. In 2015, there were an estimated 415 million people living with DM globally, with numbers set to rise to nearly 650 million by 2040 \[[@pone.0206372.ref001]\]. DM is associated with several co-morbidities, one of which is a three times higher risk of developing tuberculosis (TB) compared with the general population \[[@pone.0206372.ref002],[@pone.0206372.ref003]\]. In 2012, the population attributable fraction of DM for adult TB cases globally was estimated at 15% with the number of adult TB cases associated with DM being 1,042,000 \[[@pone.0206372.ref004]\].

Vitamin D is a secosteroid which is both synthesized in the skin by the action of sunlight and ingested in the diet. The vitamin is metabolized first in the liver to 25-hydroxycholecalciferol \[25-(OH)D~3~\] and then in the kidney to 1,25- dihydroxycholecalciferol \[1,25-(OH)~2~D~3~\], an immunologically active hormone \[[@pone.0206372.ref005]\]. In the context of DM and TB, vitamin D may have an important role. Experimental research has found that vitamin D and its metabolites regulate the function of pancreatic ß-cells and influence insulin secretion \[[@pone.0206372.ref006]\]. Vitamin D also plays a key role in human innate and adaptive immunity \[[@pone.0206372.ref005]\], and assists mononuclear phagocytes to suppress the intracellular growth of *Mycobacterium tuberculosis* (*MTB*) after initial infection \[[@pone.0206372.ref007],[@pone.0206372.ref008]\]. Recent research has found that persons with type 2 DM with low serum vitamin D levels have impaired monocyte function and therefore reduced capacity to restrict the intracellular growth of *MTB*, and this may be one of the factors linking DM to an increased risk of TB \[[@pone.0206372.ref009]\].

For several decades, there has been evidence to show that people with vitamin D deficiency have a significantly higher risk of developing active TB compared with those who have normal vitamin D levels \[[@pone.0206372.ref007],[@pone.0206372.ref008],[@pone.0206372.ref010]\]. In turn, TB patients in general have also been reported to have a higher likelihood of vitamin D deficiency compared with normal controls \[[@pone.0206372.ref011],[@pone.0206372.ref012]\]. A small scale study in urban China, using liquid chromatography-tandem mass spectrometry, reported significant differences in vitamin D levels between patients with TB, patients with TB and pre-DM and patients with TB and DM \[[@pone.0206372.ref013]\]. A larger scale multi-center study in both urban and rural China, using the electrochemiluminescence (ECLIA) method, confirmed these findings and reported that DM was a strong independent risk factor for vitamin D deficiency \[[@pone.0206372.ref014]\]. However, there have been no large scale studies looking at associations between vitamin D levels and DM related risk factors in TB patients who have DM in routine programmatic settings. Such information would be useful to determine who particularly might be at risk of developing vitamin D deficiency so that this can be prevented or better identified in the future.

We therefore conducted a study in patients with both DM and TB and aimed to determine in relation to their economically-defined residence: i) their baseline characteristics, ii) their vitamin D status and iii) whether certain baseline characteristics were associated with vitamin D deficiency.

Material and methods {#sec007}
====================

Design and settings {#sec008}
-------------------

This was a multi-centre cross-sectional study carried out in seven TB clinics and hospitals within the routine health services in Jilin Province and Beijing, China.

Seven TB clinics and hospitals in both urban and rural areas were selected for this study. The selection of the clinics and hospitals was based on the broadly defined economic development levels of the catchment areas, a sufficient proportion of TB patients with DM, the availability of essential laboratory facilities and the willingness of the staff to participate in the study without requirements of additional funding support. We selected Beijing to represent an economically well-developed area; Liaoyuan City and Tonghua City as economically better-off urban areas; Dongfeng County, Meihekou County and Tonghua County as economically better-off rural areas; and Daan County as a poverty stricken area.

Diagnosis of TB {#sec009}
---------------

All TB patients were diagnosed, registered, and managed according to the guidelines of the China National TB Control Program; which is in accordance with those recommended by the World Health Organization (WHO) \[[@pone.0206372.ref015],[@pone.0206372.ref016]\].

Diagnosis of DM {#sec010}
---------------

The diagnosis of DM was made in accordance with the WHO guidelines \[[@pone.0206372.ref017]\]. Patients were diagnosed with DM either as a result of already being diagnosed by a registered medical institution and documented in the clinic records, or as a result of a fasting blood glucose (FBG) ≥ 7.0 mmol/L being identified at the time of TB registration or at the time of TB diagnosis from another health facility regardless if they were on treatment for hyperglycaemia.

Patient recruitment {#sec011}
-------------------

TB patients with DM who were included in this study were those either presenting to TB services by themselves with symptoms suggestive of TB or having been referred from other facilities in the same or nearby catchment area. The patients included were ≥18 years and newly registered with any type and category of TB but also with DM according to national and international guidelines. In order to have accurate data on serum vitamin D levels, we excluded the following persons from the study: a) being positive for human immunodeficiency virus (HIV), b) pregnant or lactating women, c) having Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) ≥3 times the upper limit of normal level as hepatic dysfunction may alter vitamin D metabolism, d) receiving vitamin D or Vitamin D analogues for any reason, e) receiving corticosteroid treatment for any reason, and f) receiving anti-cancer therapy as many drugs disturb hepatic function which alter vitamin D metabolism.

Fasting blood glucose (FBG) and glycocylated haemoglobin (HbA1c) measurement {#sec012}
----------------------------------------------------------------------------

Venous blood samples were collected for FBG after a minimum of 10 hours overnight fast before anti-TB treatment commenced. FBG measurements were done in accordance with national guidelines which stipulate that a FBG is carried out using a venous plasma and biochemical analyzer with cut-off thresholds based on those recommended by the WHO \[[@pone.0206372.ref017]\]. Venous blood samples were collected for HbA1c as above, and HbA1c was analysed using the cation exchange method with a high performance liquid chromatography performed by G8-TOSOH, Japan \[[@pone.0206372.ref018]\].

Blood sample collection and vitamin D measurement {#sec013}
-------------------------------------------------

Five ml venous blood sample was taken immediately after their TB registration and before anti-TB treatment was started. All blood samples were taken following an overnight fast of at least 10 hours. The samples were centrifuged within 2 hours to separate the serum and stored at -70^。^C until vitamin D analysis was undertaken.

25-hydroxycholecalciferol \[25-(OH)D~3~\], was measured in the Beijing Hospital laboratory with the electrochemiluminescence (ECLIA) method that determines serum 25-(OH)D~3~ levels in a COBASE 601 Roche analyser using a chemiluminescence immunoassay (CLIA). Reagents were supplied by Roche (Switzerland) with a normal measurement range of 3--70 ng/ml. Vitamin D levels were classified according to the standard definitions of vitamin D status: 25-(OH)D~3~ ≥ 30 ng/ml = normal; 25-(OH)D~3~ between 20--29.9 ng/ml = insufficient vitamin D; 25-(OH)D~3~ between 10--19.9 ng/ml = vitamin D deficiency; 25-(OH)D~3~ between 0--9.9 ng/ml = severe vitamin D deficiency.^8^

Data collection and analysis {#sec014}
----------------------------

Individual patient data on demographic characteristics, TB symptoms, TB treatment history, complications, cigarette smoking status and DM related characteristics were collected. The data were entered to a MS Office Excel (Microsoft, Redmond, WA, USA) datasheet without patient names and other personal identifiers by the principal investigator and analysed using SPSS software for Windows, version 13 (SPSS Inc., Chicago, IL, USA). Shapiro-Wilk Test was used to examine normality distribution of vitamin D values. Nonparametric tests were used to compare median levels of vitamin D \[25-(OH)D~3~\] between groups. Categorical comparisons of various 25-(OH)D~3~ levels between DM-TB patients living in different economic areas were carried out using the chi square test. All P values are 2-tailed. Relationships between 25-(OH)D~3~ and baseline exposure variables were evaluated with odds ratios (OR) and 95% confidence intervals using logistic regression. Levels of significance were set at 5%. Variables with unadjusted ORs for which the *P* value was \<0.05 were included in a multivariate logistic regression model.

Ethics approval {#sec015}
---------------

The research proposal was approved by the health authorities in the implementing sites. The Ethics Advisory Group, International Union Against Tuberculosis and Lung Disease, Paris, France, formally approved this study (EAG number: 102/15). Patients recruited to this study were informed and agreed to participate. The Union model of Informed Consent Forms was used and signed by the patients.

Results {#sec016}
=======

There were 178 TB patients with DM consecutively registered in this study. They were 129 males (72%) and 49 females (28%). Of these, 50 were from the economically well-developed area, 103 from the economically better-off urban and rural areas and 25 from the poverty area. The mean age was 56 years (Range 25--89). Patients comprised 73 with smear-positive pulmonary TB, 92 with smear-negative pulmonary TB and 13 with extra pulmonary TB (EPTB).

Baseline characteristics in relation to the type of economical area that the patients resided in are shown in **[Table 1](#pone.0206372.t001){ref-type="table"}**. Between the different economically affected areas, there were no significant differences in patient characteristics with regards to age, gender, category of TB (new and previously treated), DM history and level of HbA1c. However, there were some significant differences in relation to urban / rural residency and type of TB. To further understand the significant differences among the three economic areas, we performed a post-test and the results are shown in **[Table 2](#pone.0206372.t002){ref-type="table"}** and **[Table 3](#pone.0206372.t003){ref-type="table"}**. There were higher proportions of patients with urban residence and confirmed smear-positive pulmonary TB in the well-developed areas compared with better-off areas and the poverty area. However, there were no significant differences between patients from better-off areas and the poverty area.

10.1371/journal.pone.0206372.t001

###### Baseline characteristics of patient s with tuberculosis (TB) and diabetes mellitus (DM) in China.

![](pone.0206372.t001){#pone.0206372.t001g}

  Characteristics     Number (%) of the patients residing in different economic areas   *χ*^2^     *P* value                       
  ------------------- ----------------------------------------------------------------- ---------- ----------- ---------- -------- ---------
  Gender              Male                                                              40(31.0)   73(56.6)    16(12.4)   2.452    0.294
  Female              10(20.4)                                                          30(61.2)   9(18.4)                         
  Age                 \<50                                                              17(29.3)   33(56.9)    8(13.8)    0.063    0.969
  ≥50                 33(27.5)                                                          70(58.3)   17(14.2)                        
  Residence           Urban                                                             35(39.3)   44(49.4)    10(11.3)   11.184   0.004
  Rural               15(16.9)                                                          59(66.2)   15(16.9)                        
  Type/Sputum smear   Positive                                                          36(49.3)   25(34.2)    12(16.5)   39.140   \<0.001
  Negative            9(9.8)                                                            70(76.1)   13(14.1)                        
  EPTB                5(38.5)                                                           8(61.5)    0                               
  Category of TB      New                                                               34(26.8)   74(58.2)    19(15.0)   0.551    0.759
  Retreatment         16(31.4)                                                          29(56.9)   6(11.7)                         
  Smoking             No                                                                23(28.0)   47(57.3)    12(14.7)   0.046    0.977
  Yes                 27(28.1)                                                          56(58.3)   13(13.6)                        
  History of DM       \< 10 years                                                       19(26.8)   38(53.5)    14(19.7)   7.463    0.113
  ≥10 years           18(37.5)                                                          24(50.0)   6(12.5)                         
  undiagnosed         13(22.0)                                                          41(69.5)   5(8.5)                          
  HbA1c               \<7.0%                                                            10(29.4)   21(61.8)    3(8.8)     1.100    0.902
  7.0--9.9%           18(26.5)                                                          40(58.8)   10(14.7)                        
  ≥10%                22(28.9)                                                          42(55.3)   12(15.8)                        

TB = tuberculosis; DM = diabetes mellitus

10.1371/journal.pone.0206372.t002

###### A post-test: Comparison of the number of patients living in different communities in relation to different economic areas.

![](pone.0206372.t002){#pone.0206372.t002g}

  Comparison group                    χ2       P value
  ----------------------------------- -------- ---------
  Well-developed VS better-off area   10.032   0.002
  Well-developed VS poverty area      6.250    0.012
  Better-off area VS poverty area     0.061    0.805

10.1371/journal.pone.0206372.t003

###### A post-test: Comparison of the number of patients with different types/smear results in relation to different economic areas.

![](pone.0206372.t003){#pone.0206372.t003g}

  Comparison group                    χ2       P value
  ----------------------------------- -------- ---------
  Well-developed VS better-off area   36.885   \<0.001
  Well-developed VS poverty area      9.728    0.006
  Better-off area VS poverty area     5.860    0.044

Amongst all the patients, 149 (84%) had vitamin D deficiency---91 (51%) with vitamin D deficiency (10--19.9 ng/ml) and 58 (33%) with severe deficiency (\< 10 ng/ml). Serum Vitamin D \[25-(OH)D~3~\] levels and proportions of patients with various grades of vitamin D deficiency in relation to where they lived in terms of economically developed / poor areas are shown in **[Table 4](#pone.0206372.t004){ref-type="table"}.** The median level (and IQR) of serum vitamin D among the 3 different economic areas was similar, but there were significantly higher proportions of patients with vitamin D deficiency or severe deficiency in the poverty area. Of the TB patients, there were 59 who were newly diagnosed with DM at the time of TB registration and their characteristics and vitamin D status are shown in **[Table 5](#pone.0206372.t005){ref-type="table"}.** They were predominantly male, aged 50 years and above and more resided in rural areas, and there was a high degree of deficiency or severe deficiency of vitamin D.

10.1371/journal.pone.0206372.t004

###### Vitamin D status in TB patients with DM, stratified by their residence in different economic areas in China.

![](pone.0206372.t004){#pone.0206372.t004g}

  -----------------------------------------------------------------------------------------------------------------------------------------
  Vitamin D status                 Patients in well- developed area\   Patients in better-off area\   Patients in poverty area\   P value
                                   N = 50                              N = 103                        N = 25                      
  -------------------------------- ----------------------------------- ------------------------------ --------------------------- ---------
  Median level (ng/ml) (IQR)       11.5 (7.08, 15.65)                  12.2 (8.80, 17.80)             11.5 (9.95, 14.55)          0.387

  No (%) with normal level\        2 (4.0)                             3 (2.9)                        0 (0)                       0.655
  (≥30ng/ml)                                                                                                                      

  No (%) with insufficiency\       6 (12.0)                            17 (16.5)                      1 (4.0)                     \<0.001
  (20--29.9ng/ml)                                                                                                                 

  No (%) with deficiency\          22 (44.0)                           51 (49.5)                      18 (72.0)                   \<0.001
  (10--19.9ng/ml)                                                                                                                 

  No (%) with severe deficiency\   20 (40.0)                           32 (31.1)                      6 (24.0)                    \<0.001
  (\<10ng/ml)                                                                                                                     
  -----------------------------------------------------------------------------------------------------------------------------------------

Vitamin D status determined by measurements of 25-(OH)D~3~. DM = Diabetes mellitus; TB = Tuberculosis; IQR = interquartile range

10.1371/journal.pone.0206372.t005

###### Characteristics of TB patients newly diagnosed with DM at the time of TB registration in China.

![](pone.0206372.t005){#pone.0206372.t005g}

  Characteristics/Categories    Number (%) of distributions   
  ----------------------------- ----------------------------- -----------
  Gender                        Male                          40 (67.8)
  Female                        19 (32.2)                     
  Residence                     Urban                         24 (40.7)
  Rural                         35 (59.3)                     
  Age                           \<50 years                    16 (27.1)
  ≥50 years                     43 (72.9)                     
  Smoking                       Yes                           30 (50.9)
  No                            29 (49.1)                     
  Serum vitamin D level         Normal ≥30ng/ml               3 (5.1)
  Insufficiency 20--29.9ng/ml   5 (8.5)                       
  Deficiency 10--19.9ng/ml      30 (50.8)                     
  Severe deficiency \<10ng/ml   21 (35.6)                     

Baseline characteristics of TB patients with DM in relation to being vitamin D deficient (25-(OH)D~3~ \<20ng/ml) are shown in **[Table 6](#pone.0206372.t006){ref-type="table"}**. The adjusted odds of a TB patient with DM having vitamin D deficiency were significantly higher in those with a longer history of DM and in those with uncontrolled DM whose HbA1c ≥10%. Other baseline characteristics such as type and category of TB, seasons of TB notification, DM treatment, FBG levels and smoking status were not associated with vitamin D status.

10.1371/journal.pone.0206372.t006

###### Baseline characteristics in TB patients with DM in relation to vitamin D deficiency (\<20ng/ml).

![](pone.0206372.t006){#pone.0206372.t006g}

  Characteristics             Total (N = 178)   No. (%) with vitamin D deficiency (N = 149)   Univariate OR (95% CI)   Multivariate OR (95% CI)   P value   
  --------------------------- ----------------- --------------------------------------------- ------------------------ -------------------------- --------- --
  Gender                      Male              129                                           108 (83.7)               Reference                            
  Female                      49                41 (83.7)                                     1.00 (0.41--2.43)                                             
  Age                         \<50 years        58                                            48 (82.8)                Reference                            
  ≥50 years                   120               101 (84.2)                                    1.11 (0.48--2.56)                                             
  Residence                   Urban             89                                            76 (85.4)                Reference                            
  Rural                       89                73 (82.0)                                     0.78 (0.35--1.74)                                             
  Type/sputum smear           Negative          92                                            77 (83.7)                Reference                            
  Positive                    73                61 (83.6)                                     0.99 (0.43--2.27)                                             
  EPTB                        13                11 (84.6)                                     1.07 (0.22--5.33)                                             
  Category of TB              New               127                                           107 (84.3)               Reference                            
  Retreatment                 51                42 (82.4)                                     0.87 (0.37--2.07)                                             
  Smoking                     No                82                                            69 (84.1)                Reference                            
  Yes                         96                80 (83.3)                                     0.94 (0.42--2.10)                                             
  Months of TB registration   May-Oct.          41                                            33 (80.5)                Reference                            
  Nov.-Apr.                   137               116 (84.7)                                    1.34 (0.54--3.30)                                             
  DM history                  \<10 years        71                                            54 (76.1)                Reference                            
  ≥10 years                   48                44 (91.7)                                     3.46 (1.09--11.04)       3.57 (1.07--11.83)         0.038     
  Undiagnosed                 59                51 (86.4)                                     2.01 (0.80--5.05)        2.57 (0.96--6.90)          0.062     
  DM treatment                Yes               117                                           97 (82.9)                Reference                            
  No                          61                52 (85.2)                                     1.19 (0.51--2.80)                                             
  FBG control                 ≤7.0 mmol/L       9                                             7 (77.8)                 Reference                            
  7.1--9.9 mmol/L             79                62 (78.5)                                     1.04 (0.20--5.48)                                             
  10.0--11.9 mmol/L           33                29 (87.9)                                     2.07 (0.31--13.68)                                            
  ≥12 mmol/L                  57                51 (89.5)                                     2.43 (0.41--14.47)                                            
  HbA1c level                 \<7.0%            34                                            25 (73.5)                Reference                            
  7.0--9.9%                   68                52 (76.5)                                     1.17 (0.45--3.01)        1.23 (0.45--3.36)          0.683     
  ≥10.0%                      76                72 (94.5)                                     6.48 (1.83--22.91)       7.31 (1.97--27.18)         0.003     

TB = tuberculosis; EPTB = extra-pulmonary tuberculosis; DM = Diabetes mellitus; OR = odds ratio; CI = confidence interval

Discussion {#sec017}
==========

This study aimed to obtain a better understanding of vitamin D status amongst TB patients with DM in the routine programme setting in China based on their residence according to economic development and baseline characteristics. There were some interesting findings.

First, there was a low median level of vitamin D in patients with dual disease, which was lower than levels found previously in non-DM patients with TB and in the general population \[[@pone.0206372.ref014],[@pone.0206372.ref019]\]. This finding is also in line with previous research findings \[[@pone.0206372.ref010],[@pone.0206372.ref012],[@pone.0206372.ref013]\]. Both DM and TB are diseases that impact on nutritional intake and both may contribute to a lower serum vitamin D level \[[@pone.0206372.ref005],[@pone.0206372.ref006]\]. A recent meta-analysis also confirmed a significantly lower serum vitamin D level in TB patients versus normal controls, but pointed out a weak association of this trend for Asian populations \[[@pone.0206372.ref012]\]. However, this was not observed in our study, and possible reasons include the poor population and accumulated risk of TB and DM \[[@pone.0206372.ref020]\]. A study in India found that no major differences in mean vitamin D levels between TB patients with DM and without DM, but the proportion of those with severe vitamin D deficiency was higher in patients with both TB and DM \[[@pone.0206372.ref021]\].

Second, about one third of all the patients regardless of their residential areas had severe vitamin D deficiency (\<10ng/ml), and this in its own right requires urgent attention. Previous research has indicated that rifampicin causes an accelerated loss of vitamin D due to increased body clearance and limited formation of the active form of vitamin D \[25-(OH)D~3~ \] \[[@pone.0206372.ref022]\]. Isoniazid can also cause impairment of 25-hydroxylation leading to impaired immunological function \[[@pone.0206372.ref023]\]. Serum vitamin D levels might also be further depressed due to enhanced negative impacts when the drugs are used in combination. Naik et al observed that the mean vitamin D level decreased 16% from the time of TB diagnosis to completion of anti-TB treatment six months later \[[@pone.0206372.ref024]\]. These findings suggest that there may be a need for vitamin D supplementation in those found with severe vitamin D deficiency at the time of TB registration \[[@pone.0206372.ref025],[@pone.0206372.ref026]\]. However, further research is required in this area, as there are conflicting reports about this aspect \[[@pone.0206372.ref011],[@pone.0206372.ref027],[@pone.0206372.ref028]\].

Third, a literature review has shown that there are low serum vitamin D levels among persons living in poor areas compared with developed areas \[[@pone.0206372.ref029]\], similar to our findings in this study. In the poverty county defined by the China State Council, there was a significantly higher proportion of DM-TB patients with vitamin D deficiency compared with patients in the other economic areas. China is a country with high incidence of TB and high prevalence of latent TB infection \[[@pone.0206372.ref030]\]. A recent meta-analysis confirmed that vitamin D deficiency is strongly associated with an increased risk of progression from latent TB infection to active TB disease with or without household contacts \[[@pone.0206372.ref012]\]. This raises the question about whether there is a need for early interventions focused on improving nutritional intake and food fortification with vitamin D supplements and requires discussion amongst policy makers.

Fourth, we did not find associations between vitamin D deficiency and baseline characteristics such as age, gender, residential community and number of daily cigarettes smoked, findings also in line with previous research \[[@pone.0206372.ref014]\]. Contrary to previous research \[[@pone.0206372.ref014],[@pone.0206372.ref028]\], we found no strong association in this study with season, possibly because most of our patients lived in urban areas which may not have been so affected by reduced nutritional intake that occurs in the winter time. In the previous report, 32.5% of the study population resided in urban areas, but the figure was 50.0% in the current study. Another intriguing finding that also requires further research was that patients with smear-positive pulmonary TB were not at increased risk of vitamin D deficiency compared with those who had smear-negative disease. This appears to be counter-intuitive as smear-positive TB tends to be associated with increased disease severity or long-term illness \[[@pone.0206372.ref031]\], which in turn might be expected to increase the risk of vitamin D deficiency.

Having a history of DM for 10 years or more or a serum glycosylated haemoglobin (HbA1c) level ≥10% were independent risk factors for vitamin D deficiency. Reasons may be as follows. Both DM and TB are associated with malnutrition and this association may be stronger with a longer duration of DM and multiple episodes of TB \[[@pone.0206372.ref032]\]. Amongst our study group, the proportion with older age and retreatment TB at nearly 30% was higher than found in a previous study of TB patients \[[@pone.0206372.ref014]\], a finding similar to that observed in Guangzhou \[[@pone.0206372.ref033]\].

HbA1c reflects average blood glucose levels over a period of 2--3 months and may be less affected by infection related hyperglycaemia \[[@pone.0206372.ref034]\]. HbA1c ≥10% represents poor glycaemic control and is an indicator for administering insulin treatment in DM patients with TB as recommended by the Union and World Diabetes Foundation. A recent systematic review highlighted that HbA1c is a reliable risk factor of all-cause mortality and cardiovascular mortality in both DM and non-DM populations \[[@pone.0206372.ref035]\]. In patients with DM, the risk of all-cause mortality increased when HbA1c levels were above 8.0% and were highest when levels were above 9.0% \[[@pone.0206372.ref035]\]. Our findings and the review suggest that a target value of HbA1c for TB patients with DM should be set at \<8.0% and clinicians need to be made aware of this fact. Unexpectedly, not being on DM treatment was not associated with vitamin D deficiency. This finding requires further study, including duration and severity of their diseases.

The strengths of this study were multi-center participation and the large number of TB patients with DM consecutively enrolled from routine programme settings to avoid selection bias. Vitamin D status was assessed according to their different economic development areas. To our knowledge, this is the first report on vitamin D status in DM-TB patients from the routine programme setting stratified by economic areas in China. There were, however, some limitations. First, for those patients newly diagnosed with DM, the diagnosis was based on FBG≥7.0 mmol/L at the time of TB notification without validation by other tests such as the oral glucose tolerance test or HbA1c. Previous research has confirmed the feasibility of taking blood samples for FBG at the time of TB diagnosis for the majority of TB patients \[[@pone.0206372.ref036]\], but the use of FBG alone to diagnose DM may underestimate the prevalence of DM by as much as 50% \[[@pone.0206372.ref037]\]. Second, we took blood samples for measurement of HbA1c immediately after the diagnosis of TB without systematically performing a physical examination. We may therefore have overlooked some conditions that influence the HbA1c level, such as iron deficiency with or without anaemia \[[@pone.0206372.ref038]\]. Third, we did not collect data on history of symptoms or signs of TB, a factor which might have impacted on vitamin D levels, nor did we analyse patient's individual food intake in relation to their vitamin D levels. Fourth, the comparison with some conditions in other published studies may not be a true comparison due to the lack of a control group. In addition, 25-(OH)D~3~ was measured with the ECLIA method only in a COBASE, and results were not confirmed with mass spectrometry, which is more accurate than the ECLIA method, due to this being unavailable in hospital settings in China.

Conclusions {#sec018}
===========

Our study found that 84% of TB patients with DM had vitamin D deficiency or severe deficiency, with the proportions being higher in patients residing in a designated poverty area compared with other areas. Those with a longer duration of DM and those showing HbA1c level ≥10% were at higher risk of vitamin D deficiency. TB Programme managers and clinicians need to pay more attention to vitamin D status in their patients, especially for those in living in poverty areas.
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